相关临床试验
0
0 进行中
药物批准
5
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Costco and not-for-profit insurer SCAN Group announced a partnership to launch a Costco-branded Medicare Advantage plan, initially in two states. - SCAN Group CEO Dr. Sachin Jain said the companies are also developing a Medigap supplemental plan for a third state, pending regulatory approval. - The collaboration builds on Costco's existing role as a preferred pharmacy for SCAN's nearly 460,000 Medicare Advantage members across five states. - The move deepens Costco's push into healthcare as some insurers scale back Medicare Advantage ambitions amid rising medical costs and tighter reimbursement.
- Walmart, Costco, Amazon, and CVS are leveraging direct-to-consumer GLP-1 programs to capture patients losing employer-sponsored coverage for weight-loss drugs like Wegovy and Zepbound. - A Mercer survey shows 6% of large employers dropped GLP-1 coverage this year, with the drugs' share of claims swelling to 11.4% from 6.9% in 2023. - Retailers view GLP-1 prescriptions as a gateway to recurring customer relationships, with pharmacy visits driving grocery and merchandise sales across their networks. - Independent pharmacies face significant disadvantages, raising safety concerns about drug interaction monitoring when patients fill GLP-1 prescriptions at multiple locations.
- Costco has launched a strategic partnership with healthcare platform Sesame and fertility network IVI RMA North America to address barriers facing the 1 in 6 Americans experiencing infertility. - The collaboration offers Costco members up to 80% savings on fertility medications like Follistim through exclusive pharmacy pricing, potentially saving thousands per treatment cycle. - Members receive coordinated care through Sesame's platform with immediate access to diagnostic workups and referrals to IVI RMA's network of fertility specialists when needed. - The program provides a streamlined pathway from initial consultation through advanced treatments like IVF and IUI, with continuous support throughout the fertility journey.
- Lumen Bioscience announced key leadership enhancements including the addition of former Microsoft executive Jeff Raikes to its board of directors following a $30 million Series C financing extension led by WestRiver Group. - The clinical-stage biotech has grown its team by nearly 39% since 2023 and opened a second GMP facility to support rising demand for clinical trial drug supplies. - The leadership expansion follows recent success of investigational LMN-201 for recurrent C. difficile infection in the Phase 2 segment of the RePreve Clinical Trial. - The company's spirulina-based platform targets multiple high-prevalence conditions including weight loss, inflammatory bowel disease, and kidney stone disease with the potential to dramatically lower costs compared to conventional biologics.
- Mail-order pharmacies achieved a satisfaction score of 697, outperforming chain drugstores by 54 points in the 2025 JD Power US Pharmacy Study. - Chain drugstores scored lowest at 643, trailing supermarkets (715) and mass merchandisers (706) significantly in customer satisfaction metrics. - Approximately 63% of customers express interest in using digital pharmacies, with Amazon Pharmacy leading brand awareness at 58%. - The satisfaction gap highlights critical issues in staffing, prescription fulfillment speed, and problem resolution at traditional chain pharmacies.
- Lumicera Health Services has partnered with Costco to expand cost-plus specialty pharmacy services, providing transparent pricing and enhanced patient support for complex medications. - The collaboration enables commercial employer benefit plans and PBMs working with Costco to access specialty medications at auditable costs, addressing the rising prices of drugs for chronic and rare conditions. - Lumicera brings over a decade of specialty pharmacy expertise and a patient support model that achieved a 85.5 net promoter score in 2024, including 24/7 support through specialized Centers of Excellence.
- The FDA has approved 61 biosimilars across 17 molecules as of December 2024, with adalimumab biosimilars increasing market share from 2% to 24% throughout the year. - Biosimilar medicines generated $12.4 billion in healthcare savings during 2023 and enabled 495 million additional days of therapy for patients who would otherwise lack access. - Major stakeholders including PBMs, healthcare providers, and regulatory agencies are collaborating to improve biosimilar adoption through streamlined development processes and enhanced market access.
